Article    Correction    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Summary for Patients    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Al-Salman, J.    Mittal, M.    Related Articles in PubMed    PubMed Citation    PubMed

BRIEF COMMUNICATION

Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report

Jameela Al-Salman, MD; Heider Arjomand, MD; David G. Kemp, MD; and Manoj Mittal, MD

18 January 2000 | Volume 132 Issue 2 | Pages 121-124

Background: Rosiglitazone maleate (Avandia, SmithKline Beecham, Philadelphia, Pennsylvania) is a new oral hypoglycemic agent approved for the treatment of type 2 diabetes. It acts primarily by increasing insulin sensitivity. In controlled trials, there has been no evidence of rosiglitazone-induced hepatocellular injury.

Objective: To report a case of hepatocellular injury in a patient receiving rosiglitazone.

Design: Case report.

Setting: Community teaching hospital.

Patient: 61-year-old man receiving rosiglitazone, 4 mg/d for 2 weeks.

Intervention: Discontinuation of rosiglitazone therapy.

Measurements: Clinical evaluation and assessment of liver function test results were done daily during hospitalization and periodically after discharge. The outpatient record was also reviewed.

Results: After receiving rosiglitazone for 2 weeks, the patient presented with anorexia, vomiting, and abdominal pain. Liver function tests revealed severe hepatocellular injury. Discontinuation of rosiglitazone therapy led to rapid improvement of liver function and resolution of symptoms.

Conclusion: Rosiglitazone may be associated with hepatocellular injury. We believe that patients receiving rosiglitazone should have liver enzyme levels monitored earlier and more frequently than initially recommended.

Author and Article Information

From Easton Hospital, MCP-Hahnemann University, Easton, Pennsylvania.

Requests for Reprints: Manoj K. Mittal, MD, Division of Gastroenterology, Easton Hospital, 250 South 21st Street, Easton, PA 18042. For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.

Current Author Addresses: Drs. Al-Salman, Arjomand, and Kemp: Department of Medicine, Easton Hospital, 250 South 21st Street, Easton, PA 18042.

Dr. Mittal: Division of Gastroenterology, Easton Hospital, 250 South 21st Street, Easton, PA 18042.

Author Contributions: Conception and design: J. Al-Salman, H. Arjomand.

Analysis and interpretation of data: J. Al-Salman, H. Arjomand, D.G. Kemp.

Drafting of the article: J. Al-Salman, H. Arjomand.

Critical revision of the article for important intellectual content: J. Al-Salman, H. Arjomand, D.G. Kemp.

Final approval of the article: J. Al-Salman, H. Arjomand, D.G. Kemp, M.K. Mittal.

Provision of study materials or patients: D.G. Kemp.

Administrative, technical, or logistic support: D.G. Kemp.

Collection and assembly of data: J. Al-Salman, H. Arjomand, D.G. Kemp.

Related articles in Annals:

Brief Communications
Hepatic Failure in a Patient Taking Rosiglitazone
Lisa M. Forman, David A. Simmons, AND Robert H. Diamond

Annals 2000 132: 118-121. [ABSTRACT][SUMMARY][Full Text]  

Summaries for Patients
Liver Injury in a Person Taking the Diabetes Drug Rosiglitazone

Annals 2000 132: 121. [Full Text]  

Letters
Correction: Liver Injury and Rosiglitazone

Annals 2000 133: 237. [Full Text]  

Letters
Rosiglitazone and Liver Failure
William L. Isley AND Julie C. Oki

Annals 2000 133: 393. [Full Text]  

Letters
Rosiglitazone and Liver Failure
Lisa M. Forman AND Robert H. Diamond

Annals 2000 133: 393-394. [Full Text]  

Letters
Rosiglitazone Toxicity
Ravi Sudhir Ravinuthala AND Uday Nori

Annals 2000 133: 658. [Full Text]  

Letters
Isolated Elevation of Alkaline Phosphatase Level Associated with Rosiglitazone
David M. Hachey, Michael P. O'Neil, AND Rex W. Force

Annals 2000 133: 752. [Full Text]  

Letters
Hepatocellular Injury in a Patient Receiving Pioglitazone
Kenji Maeda

Annals 2001 135: 306. [Full Text]  

Letters
Did This Drug Cause My Patient's Hepatitis?
Neil Kaplowitz, James H. Lewis, AND Paul B. Watkins

Annals 2003 138: 159. [Full Text]  

This article has been cited by other articles:

				K. G. Tolman, V. Fonseca, A. Dalpiaz, and M. H. Tan Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease Diabetes Care, March 1, 2007; 30(3): 734 - 743. [Full Text] [PDF]

				H. A. Spiller and T. S. Sawyer Toxicology of oral antidiabetic medications Am. J. Health Syst. Pharm., May 15, 2006; 63(10): 929 - 938. [Abstract] [Full Text] [PDF]

				M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF]

				T. R Marcy, M. L Britton, and S. M Blevins Second-Generation Thiazolidinediones and Hepatotoxicity Ann. Pharmacother., September 1, 2004; 38(9): 1419 - 1423. [Abstract] [Full Text] [PDF]

				W. M. Lee Drug-Induced Hepatotoxicity N. Engl. J. Med., July 31, 2003; 349(5): 474 - 485. [Full Text] [PDF]

				J. Sahi, C. B. Black, G. A. Hamilton, X. Zheng, S. Jolley, K. A. Rose, D. Gilbert, E. L. LeCluyse, and M. W. Sinz Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition Drug Metab. Dispos., April 1, 2003; 31(4): 439 - 446. [Abstract] [Full Text] [PDF]

				R. K. Campbell and J. White Counseling Patients With Type 2 Diabetes and Insulin Resistance in the Outpatient Setting The Diabetes Educator, November 1, 2002; 28(6): 938 - 957. [PDF]

				J D Tugwood and C T Montague Biology and toxicology of PPARg ligands Human and Experimental Toxicology, August 1, 2002; 21(8): 429 - 437. [Abstract] [PDF]

				H. E. Lebovitz, M. Kreider, and M. I. Freed Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence that rosiglitazone does not cause hepatic dysfunction Diabetes Care, May 1, 2002; 25(5): 815 - 821. [Abstract] [Full Text] [PDF]

				A. A. Parulkar, M. L. Pendergrass, R. Granda-Ayala, T. R. Lee, and V. A. Fonseca Nonhypoglycemic Effects of Thiazolidinediones Ann Intern Med, January 2, 2001; 134(1): 61 - 71. [Abstract] [Full Text] [PDF]

				M. J. Lenhard and W. B. Funk Failure to Develop Hepatic Injury From Rosiglitazone in a Patient With a History of Troglitazone-Induced Hepatitis Diabetes Care, January 1, 2001; 24(1): 168 - 169. [Full Text]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				D. M. Hachey, M. P. O'Neil, and R. W. Force Isolated Elevation of Alkaline Phosphatase Level Associated with Rosiglitazone Ann Intern Med, November 7, 2000; 133(9): 752 - 752. [Full Text] [PDF]

				R. S. Ravinuthala and U. Nori Rosiglitazone Toxicity Ann Intern Med, October 17, 2000; 133(8): 658 - 658. [Full Text] [PDF]

				W. L. Isley and J. C. Oki Rosiglitazone and Liver Failure Ann Intern Med, September 5, 2000; 133(5): 393 - 393. [Full Text] [PDF]

				E. Arioglu, J. Duncan-Morin, N. Sebring, K. I. Rother, N. Gottlieb, J. Lieberman, D. Herion, D. E. Kleiner, J. Reynolds, A. Premkumar, et al. Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes Ann Intern Med, August 15, 2000; 133(4): 263 - 274. [Abstract] [Full Text] [PDF]

				S. Campbell Management of Type 2 Diabetes in the Geriatric Patient Journal of Pharmacy Practice, August 1, 2000; 13(4): 263 - 276. [Abstract] [PDF]

				Correction: Liver Injury and Rosiglitazone Ann Intern Med, August 1, 2000; 133(3): 237 - 237. [Full Text] [PDF]

				Is Rosiglitazone Hepatotoxic, Too? Journal Watch Gastroenterology, April 1, 2000; 2000(401): 18 - 18. [Full Text]

				Is Rosiglitazone Hepatotoxic, Too? Journal Watch (General), February 1, 2000; 2000(201): 1 - 1. [Full Text]